# LIraglutide and Beta-cell RepAir (LIBRA) Study

> **NCT01270789** · PHASE3 · COMPLETED · sponsor: **Mount Sinai Hospital, Canada** · enrollment: 63 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Liraglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01270789
- **Lead sponsor:** Mount Sinai Hospital, Canada
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-12
- **Final completion:** 2014-05
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2014-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01270789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01270789, "LIraglutide and Beta-cell RepAir (LIBRA) Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01270789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*